Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

245.44 +0.18 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Via Benzinga
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by 
Via Benzinga
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution
Via Benzinga
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
Alnylam Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback